(S (NP (NP (ADJP (NNP Model) (HYPH -) (VBN informed)) (NN precision) (NN dosing) (PRN (-LRB- -LRB-) (NP (NNP MIPD)) (-RRB- -RRB-))) (VP (VBG using) (NP (JJ therapeutic) (NML (NN drug) (HYPH /) (NN biomarker)) (NN monitoring)))) (VP (VBZ offers) (NP (DT the) (NN opportunity) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB improve) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NN drug) (NNS therapies))))))))) (. .))
(S (NP (JJ Current) (NNS strategies)) (VP (VP (VBP comprise) (NP (ADJP (NP (NN model)) (HYPH -) (VBN informed)) (NN dosing) (NNS tables))) (CC or) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (JJ maximum) (NN a-posteriori) (NNS estimates)))))) (. .))
(S (NP (DT These) (NNS approaches)) (, ,) (ADVP (RB however)) (, ,) (VP (VP (VBP lack) (NP (NP (DT a) (NN quantification)) (PP (IN of) (NP (NN uncertainty))))) (CONJP (CC and) (HYPH /) (CC or)) (VP (VB consider) (NP (NP (JJ only) (NN part)) (PP (IN of) (NP (DT the) (JJ available) (ADJP (NN patient) (HYPH -) (JJ specific)) (NN information)))))) (. .))
(S (NP (PRP We)) (VP (VBP propose) (NP (NP (CD three) (JJ novel) (NNS approaches)) (PP (IN for) (NP (NNP MIPD)))) (S (VP (VBG employing) (NP (NP (NML (NML (JJ Bayesian) (NNS data)) (NN assimilation)) (-LRB- -LRB-) (NN DA) (-RRB- -RRB-)) (CONJP (CC and) (HYPH /) (CC or)) (NP (NN reinforcement) (NN learning) (PRN (-LRB- -LRB-) (NP (NN RL)) (-RRB- -RRB-)))) (S (VP (TO to) (VP (VB control) (NP (NP (NNS neutropenia)) (, ,) (NP (NP (DT the) (JJ major) (ADJP (NN dose) (HYPH -) (VBG limiting)) (NN side) (NN effect)) (PP (IN in) (NP (JJ anticancer) (NN chemotherapy))))))))))) (. .))
(S (NP (DT These) (NNS approaches)) (VP (VBP have) (NP (DT the) (NN potential) (S (VP (TO to) (ADVP (RB substantially)) (VP (VB reduce) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (ADJP (NN life) (HYPH -) (VBG threatening)) (NN grade) (CD 4)) (CC and) (NP (JJ subtherapeutic) (NML (NN grade) (CD 0)) (NNS neutropenia))))) (PP (VBN compared) (PP (IN to) (NP (VBG existing) (NNS approaches))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB further)) (VP (VBP show) (SBAR (IN that) (S (NP (NN RL)) (VP (VBZ allows) (S (VP (TO to) (VP (VB gain) (NP (JJ further) (NNS insights)) (PP (IN by) (S (VP (VBG identifying) (NP (NP (JJ patient) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (VBP drive) (NP (NN dose) (NNS decisions)))))))))))))))) (. .))
(S (PP (IN Due) (PP (IN to) (NP (PRP$ its) (NN flexibility)))) (, ,) (NP (NP (DT the) (VBN proposed) (VBN combined) (NN DA) (HYPH -) (NN RL)) (NP (NN approach))) (VP (MD can) (ADVP (RB easily)) (VP (VB be) (VP (VBN extended) (S (VP (TO to) (VP (VB integrate) (S (NP (NP (JJ multiple) (NNS endpoints)) (CC or) (NP (ADJP (NN patient) (HYPH -) (VBN reported)) (NNS outcomes))) (, ,) (ADVP (RB thereby)) (VP (VBG promising) (NP (NP (JJ important) (NNS benefits)) (PP (IN for) (NP (JJ future) (VBN personalized) (NNS therapies)))))))))))) (. .))
